207_Combined course Presentations

Toxicity of concurrent SRT and antibody therapy

Anti-Her2 (trastuzumab)

 Very limited available data does not indicate increased toxicity of cranial SRT combined with trastuzumab.

 Data on trastuzumab and extra-cranial SRT is lacking.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37